UBI Pharma was established on July 31, 2014 as a spin-off company from United Biomedical, Inc., Asia. UBI Pharma specializes in developing and manufacturing fusion protein drugs and formulations of small molecule pharmaceuticals.

UBI Pharma is dedicated to developing biobetters and specialty injectables on exclusively owned long-acting protein drug platforms, such as fusion proteoglycan, fusion single Fc chain, and new formulations. UBI Pharma has the only US FDA approved sterile injectables manufacturing line in Asia outside of Japan. These patented platforms, in combination with our manufacturing experience and the clinical resources in Taiwan, are paving the way for UBI Pharma’s success in the global market.